Table 3.
Comparisons of the incidence rate of MACE in each BP classification stratified based on each age and sex.
| Group | Age groups | Sex | ||||
|---|---|---|---|---|---|---|
| 40–49 | 50–59 | 60–69 | 70+ | Male | Female | |
| No. of subjects | 173,444 | 92,797 | 48,853 | 12,234 | 180,766 | 146,562 |
| Normal BP | Reference | Reference | Reference | Reference | Reference | Reference |
| Elevate BP | 1.14 (0.97–1.35) | 1.12 (0.95–1.35) | 1.01 (0.83–1.23) | 0.88 (0.62–1.22) | 1.04 (0.92–1.17) | 1.12 (0.95–1.32) |
| Stage 1 HTN | 1.34 (1.20–1.50) | 1.18 (1.05–1.34) | 1.28 (1.12–1.47) | 1.22 (0.98–1.52) | 1.19 (1.10–1.30) | 1.30 (1.16–1.46) |
| Stage 2 HTN | 2.03 (1.78–2.31) | 1.71 (1.49–1.96) | 1.52 (1.32–1.76) | 1.56 (1.25–1.95) | 1.70 (1.56–1.86) | 1.51 (1.31–1.73) |
The models was conducted with time-varying Cox analysis after adjusting age, sex, BMI, total cholesterol, fasting glucose, smoking status, drinking habit, CCI and calendar year.
MACE major adverse cardiovascular events, HTN hypertension, BP blood pressure, CI confidence interval, BMI body mass index, CCI Charlson comorbidity index, No. number.